Whoop has moved beyond its athlete-focused marketing to enroll in Medicare’s ACCESS pilot. The company will make its wearable and services available at low or no cost to many traditional Medicare beneficiaries aged 65 and older. Under the program, Whoop will provide each enrolled patient with a wearable device, a 12-month subscription to its app, and access to clinicians who can interpret data and offer advice. Medicare will pay participating companies based on health outcomes rather than simple device distribution — a structural shift that ties reimbursement to clinical results.
The ACCESS pilot is a 10-year program and the directory of initial participants lists 55 companies that will deliver chronic condition management under this model. Whoop reported it will serve patients with risk factors including high blood pressure, high cholesterol, obesity, and prediabetes. The source did not report the specific enrollment criteria, sample sizes, or how Whoop will operationalize patient selection within Medicare’s beneficiary population.
Ami Bhatt, Whoop’s chief medical officer, told STAT Summit attendees the company’s immediate roadmap emphasizes simplification of the app experience for older users. She noted surveys indicate many members of older generations trust clinicians with their data; the practical barrier, Bhatt said, is making it easy for that population to share and act on data. Whoop is working with the National Council on Aging and AARP to tailor experiences toward older adults’ priorities rather than imposing a single set of goals.
Bhatt described a shift in corporate responsibility: “Whoop takes responsibility for, in 12 months, I am going to make these people better,” she said. To receive full payment under ACCESS, Whoop must show improvement or control in measures tied to chronic conditions. The source specifies three target metrics companies will be evaluated on: blood pressure, hemoglobin A1C, and low-density lipoprotein cholesterol (LDL). The article did not provide exact quantitative thresholds, statistical targets, nor the methodology Whoop will use to validate those changes for Medicare reimbursement.
Whoop’s pivot to a Medicare population comes after recent fundraising and regulatory developments. The company raised $575 million from investors including Mayo Clinic and the sovereign wealth fund of Qatar; Bhatt said those resources are being applied to develop experiences tailored to older adults and to demonstrate outcomes. Whoop also recently added the ability for users to discuss their wearable data with clinicians—a functionality that arrived just prior to the FDA closing a warning letter related to Whoop’s blood pressure-estimating feature. The source reports the FDA initially considered that feature to qualify as a medical device but then dropped enforcement after Whoop adjusted the product.
Bhatt, who previously chaired the FDA’s digital health advisory committee and served as the American College of Cardiology’s chief innovation officer, framed the move as bridging wellness and clinical care. She noted that Whoop historically positioned its product in the wellness category; the ACCESS model compels the company to demonstrate clinical outcomes that can be tied to reduced cardiovascular risk, stroke risk, or other measurable endpoints.
Whoop users are highly engaged with the product, Bhatt said; app-check frequency is substantial. But she also warned that engagement alone does not guarantee improved health — research on continuous glucose monitors provides an example where adoption and usage did not automatically equal outcome benefit. Bhatt argued that true value requires measurable changes in clinical metrics.
As a practicing physician, Bhatt described the burden continuous streams impose on clinicians. Patients who compile and print binders of wearable data create more work than actionable insight in a brief visit. Her proposal is pragmatic: synthesize continuous streams into clinician-ready, contextualized reports that combine summarized physiological data, patient journaling, and coaching interactions. The source reports Bhatt’s belief that such comprehensive summaries could give clinicians the specific signals they need during short appointments — turning raw data into usable clinical inputs.
The article lays out ambition and structure but leaves several operational details unspecified. The source did not report Whoop’s trial protocols, sample sizes, statistical significance targets, or precise payment thresholds tied to outcome performance under ACCESS. It also did not describe how Whoop will integrate its clinician-facing reports into electronic health records or how primary care teams will be reimbursed for time spent acting on wearable-derived insights.
Medicare’s ACCESS model does mandate outcome demonstration for full payment, and Whoop has publicly committed to showing change in blood pressure, hemoglobin A1C, and LDL over a 12-month subscription period. What remains to be reported are the rigorous metrics that will define success, the operational workflow for clinician review, and whether high engagement will translate into improved chronic disease control at scale. Those questions are central to whether consumer wearables can move from wellness tools into reproducibly effective clinical interventions for older adults.